Faina Nakhlis, M.D.

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 983-7777

fnakhlis@partners.org

Dana-Farber Cancer Institute
Phone: (617) 983-7777

fnakhlis@partners.org

Faina Nakhlis, M.D.

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

Assistant Professor, Surgery, Harvard Medical School

DF/HCC PROGRAM AFFILIATION

Breast Cancer, Member

Research Abstract

My research interests include the natural history and surgical management of premalignant breast lesions, inflammatory breast cancer (IBC), local therapy for metastatic locally advanced breast cancer, the mechanisms of tumor resistance.

Nakhlis F, Baker GM, Pilewskie M, Gelman R, Calvillo KZ, Ludwig K, McAuliffe PF, Willey S, Rosenberger LH, Parker C, Gallagher K, Jacobs L, Feldman S, Lange P, DeSantis SD, Schnitt SJ, King TA. The Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In Situ in Patients with Intraductal Papilloma without Atypia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 034). Ann Surg Oncol 2020. PubMed
White RE, Warren L, Nakhlis F, Rosenbluth J, Bellon J, Block C, Overmoyer B. Characteristics associated with inflammatory breast cancer (IBC): An epidemiologic study from a dedicated IBC program. Breast J 2020. PubMed
Lagendijk M, Desantis S, Nakhlis F, Duggan M, Calvillo KZ, Carty M, Chun Y, Caterson S, Golshan M, Dominici LS. Impact of surgical complications on patient reported outcomes (PROs) following nipple sparing mastectomy. Am J Surg 2020. PubMed
Jacene HA, DiPiro PJ, Bellon J, Hu J, Cheng SC, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth JM, Yeh E, Overmoyer B. Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning. Breast Cancer Res Treat 2020; 181:383-390. PubMed
Fayanju OM, Ren Y, Greenup RA, Plichta JK, Rosenberger LH, Force J, Suneja G, Devi GR, King TA, Nakhlis F, Hyslop T, Hwang ES. Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. Breast Cancer Res Treat 2020; 180:207-217. PubMed
Harrison BT, Nakhlis F, Dillon DA, Soong TR, Garcia EP, Schnitt SJ, King TA. Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations. Mod Pathol 2020. PubMed
Omranipour R, Alipour S, Ensani F, Nakhlis F. Premalignant Disorders of the Breast in Pregnancy and Lactation. Adv Exp Med Biol 2020; 1252:63-72. PubMed
Nakhlis F, Regan MM, Chun YS, Dominici LS, Caterson S, Bellon JR, Warren L, Yeh ED, Jacene HA, King TA, Overmoyer B. Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience. Breast J 2019. PubMed
Mamtani A, Nakhlis F, Downs-Canner S, Zabor EC, Morrow M, King TA, Van Zee KJ. Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion. Ann Surg Oncol 2019. PubMed
Laws A, Hughes ME, Hu J, Barry WT, Dominici L, Nakhlis F, Barbie T, Duggan M, Weiss A, Rhei E, Carter K, Nimbkar S, Schnitt SJ, King TA. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Ann Surg Oncol 2019. PubMed
Schonberg MA, Freedman RA, Recht AR, Jacobson AR, Aliberti GM, Karamourtopoulos M, Nakhlis F, McCarthy EP, Pories SE, Sharma R, Dominici LS. Developing a patient decision aid for women aged 70 and older with early stage, estrogen receptor positive, HER2 negative, breast cancer. 2019. PubMed

Jacene HA, Youn T, DiPiro PJ, Hu J, Cheng SC, Franchetti Y, Shah H, Bellon JR, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth J, Yeh E, Overmoyer B, . Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade. Clin Breast Cancer 2018. PubMed
Nakhlis F, Harrison BT, Giess CS, Lester SC, Hughes KS, Coopey SB, King TA. Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ. Ann Surg Oncol 2018. PubMed
Laws A, Anderson K, Hu J, McLean K, Novak L, Dominici LS, Nakhlis F, Carty M, Caterson S, Chun Y, Duggan M, Barry W, Connell N, Golshan M, King TA. Implementation of a Venous Thromboembolism Prophylaxis Protocol Using the Caprini Risk Assessment Model in Patients Undergoing Mastectomy. Ann Surg Oncol 2018. PubMed
Grossmith S, Nguyen A, Hu J, Plichta JK, Nakhlis F, Cutone L, Dominici L, Golshan M, Duggan M, Carter K, Rhei E, Barbie T, Calvillo K, Nimbkar S, Bellon J, Wong J, Punglia R, Barry W, King TA. Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series. Ann Surg Oncol 2018. PubMed
Moossdorff M, Nakhlis F, Hu J, Barry WT, Losk K, Haskett C, Smidt ML, King TA. The Potential Impact of AMAROS on the Management of the Axilla in Patients with Clinical T1-2N0 Breast Cancer Undergoing Primary Total Mastectomy. Ann Surg Oncol 2018. PubMed
Nakhlis F. How Do We Approach Benign Proliferative Lesions? Curr Oncol Rep 2018; 20:34. PubMed
Li GZ, Wong SM, Lester S, Nakhlis F. Evaluating the risk of underlying malignancy in patients with pathologic nipple discharge. Breast J 2018. PubMed
Fairweather M, Jiang W, Keating NL, Freedman RA, King TA, Nakhlis F. Morbidity of local therapy for locally advanced metastatic breast cancer: an analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare Registry. Breast Cancer Res Treat 2018. PubMed
Keene KS, King T, Hwang ES, Peng B, McGuire KP, Tapia C, Zhang H, Bae S, Nakhlis F, Klauber-Demore N, Meszoely I, Sabel MS, Willey SC, Eterovic AK, Hudis C, Wolff AC, De Los Santos J, Thompson A, Mills GB, Meric-Bernstam F. Molecular determinants of post-mastectomy breast cancer recurrence. NPJ Breast Cancer 2018; 4:34. PubMed
Nakhlis F, Regan MM, Warren LE, Bellon JR, Hirshfield-Bartek J, Duggan MM, Dominici LS, Golshan M, Jacene HA, Yeh ED, Mullaney EE, Overmoyer B. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer. Ann Surg Oncol 2017. PubMed
Nakhlis F, Lester S, Denison C, Wong SM, Mongiu A, Golshan M. Complex sclerosing lesions and radial sclerosing lesions on core needle biopsy: Low risk of carcinoma on excision in cases with clinical and imaging concordance. Breast J 2017. PubMed
Nakhlis F, Gilmore L, Gelman R, Bedrosian I, Ludwig K, Hwang ES, Willey S, Hudis C, Iglehart JD, Lawler E, Ryabin NY, Golshan M, Schnitt SJ, King TA. Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020). Ann Surg Oncol 2015. PubMed
Warren LE, Guo H, Regan MM, Nakhlis F, Yeh ED, Jacene HA, Hirshfield-Bartek J, Overmoyer BA, Bellon JR. Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management. Ann Surg Oncol 2015. PubMed
Nakhlis F, Ahmadiyeh N, Lester S, Raza S, Lotfi P, Golshan M. Papilloma on core biopsy: excision vs. observation. Ann Surg Oncol 2015; 22:1479-82. PubMed
Warren LE, Guo H, Regan MM, Nakhlis F, Yeh ED, Jacene HA, Hirshfield-Bartek J, Overmoyer BA, Bellon JR. Inflammatory breast cancer and development of brain metastases: risk factors and outcomes. Breast Cancer Res Treat 2015; 151:225-32. PubMed
Golshan M, Nakhlis F. Can methylene blue only be used in sentinel lymph node biopsy for breast cancer? Breast J 2006; 12:428-30. PubMed
Yeh ED, Jacene HA, Bellon JR, Nakhlis F, Birdwell RL, Georgian-Smith D, Giess CS, Hirshfield-Bartek J, Overmoyer B, Van den Abbeele AD. What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach. Radiographics 2013; 33:2003-17. PubMed

Hide

Faina Nakhlis, M.D.

Dana-Farber Cancer Institute

Similar Members

Similar Members

Faina Nakhlis, M.D.

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

DF/HCC PROGRAM AFFILIATION

Research Abstract

Publications

Similar Members

Similar Members